This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Side effects of carbimazole / propylthiouracil

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Both drugs have similar side effects.

  • Agranulocytosis is dangerous and affects about 0.3 in 1000 patients (1). It is not predicted from routine WBC measurements and should be suspected in patients on high doses presenting with a sore throat, mouth ulcer or any serious infection. The risk of agranulocytosis is lower with carbimazole than with propylthiouracil. Agranulocytosis is an absolute contraindication to further treatment with antithyroid drugs and treatment with radio-iodine should be given

  • An itchy maculopapular skin rash occurs in 1-5% if cases.

Less common side effects may include:

  • arthralgia
  • nausea and vomiting
  • fever
  • jaundice
  • vomiting
  • alopecia
  • carbimazole - congenital malformations reported associated with use of carbimazole include aplasia cutis congenita (absence of a portion of skin, often localised on the head), craniofacial malformations (choanal atresia; facial dysmorphism), defects of the abdominal wall and gastrointestinal tract (exomphalos, oesophageal atresia, omphalo-mesenteric duct anomaly), and ventricular septal defect (2)

 

Reference:

  • Current Problems in Pharmacovigilance (February 1999), 25, 1-4.
  • MRHA (February 2019). Drug Safety Update 12(7):1-8

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.